{"id":"vindesine","rwe":[],"tags":[{"label":"vindesine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Cytochrome P450 3A4","category":"target"},{"label":"CYP3A4","category":"gene"},{"label":"L01CA03","category":"atc"},{"label":"Active","category":"status"},{"label":"Acute lymphoid leukemia","category":"indication"},{"label":"Chronic myeloid leukemia","category":"indication"},{"label":"Malignant melanoma","category":"indication"},{"label":"Malignant tumor of lung","category":"indication"},{"label":"Antimitotic Agents","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Antineoplastic Agents, Phytogenic","category":"pharmacology"},{"label":"Tubulin Modulators","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":910.236,"date":"","count":240,"signal":"Myelosuppression","source":"DrugCentral FAERS","actionTaken":"Reported 240 times (LLR=910)"},{"llr":476.12,"date":"","count":156,"signal":"Bone marrow failure","source":"DrugCentral FAERS","actionTaken":"Reported 156 times (LLR=476)"},{"llr":202.796,"date":"","count":109,"signal":"Leukopenia","source":"DrugCentral FAERS","actionTaken":"Reported 109 times (LLR=203)"},{"llr":147.014,"date":"","count":111,"signal":"Febrile neutropenia","source":"DrugCentral FAERS","actionTaken":"Reported 111 times (LLR=147)"},{"llr":114.712,"date":"","count":52,"signal":"Agranulocytosis","source":"DrugCentral FAERS","actionTaken":"Reported 52 times (LLR=115)"},{"llr":83.697,"date":"","count":75,"signal":"White blood cell count decreased","source":"DrugCentral FAERS","actionTaken":"Reported 75 times (LLR=84)"},{"llr":74.948,"date":"","count":133,"signal":"Pyrexia","source":"DrugCentral FAERS","actionTaken":"Reported 133 times (LLR=75)"},{"llr":71.022,"date":"","count":30,"signal":"Aspergillus infection","source":"DrugCentral FAERS","actionTaken":"Reported 30 times (LLR=71)"},{"llr":70.739,"date":"","count":63,"signal":"Stomatitis","source":"DrugCentral FAERS","actionTaken":"Reported 63 times (LLR=71)"},{"llr":65.91,"date":"","count":45,"signal":"Mucosal inflammation","source":"DrugCentral FAERS","actionTaken":"Reported 45 times (LLR=66)"},{"llr":61.678,"date":"","count":97,"signal":"Anaemia","source":"DrugCentral FAERS","actionTaken":"Reported 97 times (LLR=62)"},{"llr":58.412,"date":"","count":73,"signal":"Thrombocytopenia","source":"DrugCentral FAERS","actionTaken":"Reported 73 times (LLR=58)"},{"llr":53.319,"date":"","count":42,"signal":"Neutrophil count decreased","source":"DrugCentral FAERS","actionTaken":"Reported 42 times (LLR=53)"},{"llr":50.765,"date":"","count":28,"signal":"Neurotoxicity","source":"DrugCentral FAERS","actionTaken":"Reported 28 times (LLR=51)"},{"llr":50.217,"date":"","count":22,"signal":"Second primary malignancy","source":"DrugCentral FAERS","actionTaken":"Reported 22 times (LLR=50)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=VINDESINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:58:49.950332+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Vindesine","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T01:58:57.679624+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T01:59:05.583528+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:58:56.281226+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=VINDESINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:58:56.614522+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3989543/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:58:57.325830+00:00"}},"allNames":"eldisine","offLabel":[],"synonyms":["eldisine","desacetylvinblastine amide","vindesine sulfate","vindesine","compound 112531"],"timeline":[{"date":"1979-01-01","type":"positive","source":"DrugCentral","milestone":"YEAR INTRODUCED approval"}],"aiSummary":"Eldisine is a small molecule used in cancer treatment. It has been studied in combination with Rituximab, Mitoxantrone hydrochloride liposome, and Cyclophosphamide for the treatment of various conditions, including Diffuse Large B-cell Lymphoma, Leukemia, Neuroblastoma, and Adult T-cell Leukemia/Lymphoma.","approvals":[{"date":"1979-01-01","orphan":false,"company":"","regulator":"YEAR INTRODUCED"}],"brandName":"Eldisine","ecosystem":[{"indication":"Acute lymphoid leukemia","otherDrugs":[{"name":"asparaginase","slug":"asparaginase","company":"Merck"},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone acetate","slug":"betamethasone-acetate","company":""},{"name":"clofarabine","slug":"clofarabine","company":"Genzyme"}],"globalPrevalence":null},{"indication":"Chronic myeloid leukemia","otherDrugs":[{"name":"cyclophosphamide","slug":"cyclophosphamide","company":"Baxter Hlthcare"},{"name":"hydroxycarbamide","slug":"hydroxycarbamide","company":"Bristol Myers Squibb"},{"name":"mechlorethamine","slug":"mechlorethamine","company":"Recordati Rare"},{"name":"omacetaxine mepesuccinate","slug":"omacetaxine-mepesuccinate","company":"Ivax Intl"}],"globalPrevalence":480000},{"indication":"Malignant melanoma","otherDrugs":[{"name":"hydroxycarbamide","slug":"hydroxycarbamide","company":"Bristol Myers Squibb"},{"name":"interferon alfa-2b","slug":"interferon-alfa-2b","company":"Schering"},{"name":"talimogene laherparepvec","slug":"talimogene-laherparepvec","company":"Amgen"}],"globalPrevalence":330000},{"indication":"Malignant tumor of lung","otherDrugs":[{"name":"doxorubicin","slug":"doxorubicin","company":""},{"name":"mechlorethamine","slug":"mechlorethamine","company":"Recordati Rare"},{"name":"methotrexate","slug":"methotrexate","company":"Dava Pharms Inc"}],"globalPrevalence":null}],"mechanism":{"target":"Cytochrome P450 3A4","targets":[{"gene":"CYP3A4","source":"DrugCentral","target":"Cytochrome P450 3A4","protein":"Cytochrome P450 3A4"}],"modality":"Small Molecule","drugClass":"vindesine","explanation":"","oneSentence":"","technicalDetail":"Vindesine is a vinca alkaloid that acts as a microtubule inhibitor, disrupting the dynamics of microtubule assembly and disassembly, which is essential for cell division and proliferation."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Vindesine","title":"Vindesine","extract":"Vindesine, also termed Eldisine, is a semisynthetic vinca alkaloid derived from the flowering plant Catharanthus roseus. Like the natural and semisynthetic vinca alkaloids derived from this plant, vindesine is an inhibitor of mitosis that is used as a chemotherapy drug. By inhibiting mitosis, vinedsine blocks the proliferation of cells, particularly the rapidly proliferation cells of certain types of cancer. It is used, generally in combination with other chemotherapeutic drugs, in the treatment of various malignancies such as leukaemia, lymphoma, melanoma, breast cancer, and lung cancer."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2826","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=VINDESINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=VINDESINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Vindesine","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T16:09:18.582731","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:59:05.583642+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"vinblastine","drugSlug":"vinblastine","fdaApproval":"1965-11-05","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"vincristine","drugSlug":"vincristine","fdaApproval":"1963-07-10","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"vinorelbine","drugSlug":"vinorelbine","fdaApproval":"1994-12-23","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"vindesine","indications":{"approved":[{"name":"Acute lymphoid leukemia","source":"DrugCentral","snomedId":91857003,"regulator":"FDA"},{"name":"Chronic myeloid leukemia","source":"DrugCentral","snomedId":92818009,"regulator":"FDA","usPrevalence":null,"globalPrevalence":480000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG])"},{"name":"Malignant melanoma","source":"DrugCentral","snomedId":372244006,"regulator":"FDA","usPrevalence":100000,"globalPrevalence":330000,"prevalenceMethod":"curated","prevalenceSource":"IARC GLOBOCAN, 2022"},{"name":"Malignant tumor of lung","source":"DrugCentral","snomedId":363358000,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"vinblastine","brandName":"vinblastine","genericName":"vinblastine","approvalYear":"1965","relationship":"same-class"},{"drugId":"vincristine","brandName":"vincristine","genericName":"vincristine","approvalYear":"1963","relationship":"same-class"},{"drugId":"vinorelbine","brandName":"vinorelbine","genericName":"vinorelbine","approvalYear":"1994","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06985485","phase":"PHASE2","title":"Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-05-17","conditions":["Acute Lymphoblastic Leukemia","Immunotherapy","Blinatumomab","Inotuzumab Ozogamicin"],"enrollment":26,"completionDate":"2027-12-31"},{"nctId":"NCT05681260","phase":"PHASE3","title":"Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2023-02-06","conditions":["T-cell Lymphoblastic Lymphoma"],"enrollment":200,"completionDate":"2029-12-31"},{"nctId":"NCT02845882","phase":"PHASE3","title":"LBL-2016 for Children or Adolescents in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2016-01","conditions":["Lymphoblastic Lymphoma"],"enrollment":150,"completionDate":"2031-12"},{"nctId":"NCT02881086","phase":"PHASE3","title":"Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment","status":"COMPLETED","sponsor":"Goethe University","startDate":"2016-08","conditions":["Acute Lymphoblastic Leukemia","Lymphoblastic Lymphoma"],"enrollment":1023,"completionDate":"2024-12"},{"nctId":"NCT07159620","phase":"PHASE2","title":"Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-09-01","conditions":["Adult T-cell Leukemia/Lymphoma"],"enrollment":27,"completionDate":"2030-09-01"},{"nctId":"NCT07059156","phase":"PHASE2,PHASE3","title":"Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-06-01","conditions":["Acute Lymphoblastic Leukemia, Adult"],"enrollment":50,"completionDate":"2027-07"},{"nctId":"NCT04221035","phase":"PHASE3","title":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2019-11-05","conditions":["High-Risk Neuroblastoma","Patient With Insufficient Response Chemoimmunotherapy"],"enrollment":800,"completionDate":"2032-11"},{"nctId":"NCT07004075","phase":"PHASE3","title":"FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","startDate":"2025-06-30","conditions":["Low-grade Glioma","Pediatric Low-grade Gliomas","pLGG With BRAF Alteration"],"enrollment":102,"completionDate":"2029-04-30"},{"nctId":"NCT06918015","phase":"PHASE2","title":"Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-05-01","conditions":["BTK Inhibitors","Follicular Lymphoma","Immunochemotherapy"],"enrollment":58,"completionDate":"2030-05-01"},{"nctId":"NCT03643276","phase":"PHASE3","title":"Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017","status":"RECRUITING","sponsor":"Martin Schrappe","startDate":"2018-07-15","conditions":["Acute Lymphoblastic Leukemia, Pediatric"],"enrollment":5000,"completionDate":"2028-07-14"},{"nctId":"NCT03206671","phase":"PHASE3","title":"Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital Muenster","startDate":"2017-08-03","conditions":["Mature B-cell Non-Hodgkin Lymphoma"],"enrollment":650,"completionDate":"2027-06"},{"nctId":"NCT04043494","phase":"PHASE3","title":"International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"University Hospital Muenster","startDate":"2019-08-23","conditions":["Lymphoblastic Lymphoma, Childhood"],"enrollment":683,"completionDate":"2027-11-22"},{"nctId":"NCT06361329","phase":"PHASE3","title":"Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-04-03","conditions":["ETP-ALL"],"enrollment":81,"completionDate":"2027-03-31"},{"nctId":"NCT06739265","phase":"PHASE1,PHASE2","title":"Golidocitinib Plus CHOP in Newly Diagnosed PTCL","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-09-01","conditions":["Peripheral T-cell Lymphoma"],"enrollment":68,"completionDate":"2027-09-01"},{"nctId":"NCT06713057","phase":"PHASE2","title":"Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2024-12-01","conditions":["Locally Advanced Thyroid Gland Carcinoma","Thyroid Cancer"],"enrollment":20,"completionDate":"2026-07-01"},{"nctId":"NCT06674096","phase":"PHASE2","title":"RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-11-06","conditions":["Double-expressor Lymphoma"],"enrollment":44,"completionDate":"2030-06-30"},{"nctId":"NCT06176027","phase":"PHASE1,PHASE2","title":"Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas","status":"RECRUITING","sponsor":"Navy General Hospital, Beijing","startDate":"2024-10-01","conditions":["Relapsed Peripheral T-Cell Lymphomas","Refractory Peripheral T-Cell Lymphomas"],"enrollment":52,"completionDate":"2030-09-01"},{"nctId":"NCT05557110","phase":"PHASE2","title":"Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL","status":"COMPLETED","sponsor":"Chen Suning","startDate":"2022-09-08","conditions":["B Acute Lymphoblastic Leukemia"],"enrollment":35,"completionDate":"2024-03-31"},{"nctId":"NCT06486337","phase":"PHASE2","title":"CMOP±R in the Treatment of Untreated Non-Hodgkin's Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-07-10","conditions":["NHL"],"enrollment":197,"completionDate":"2027-08-31"},{"nctId":"NCT06433362","phase":"PHASE2","title":"CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-06-01","conditions":["Peripheral T Cell Lymphoma"],"enrollment":115,"completionDate":"2026-06-30"},{"nctId":"NCT05290090","phase":"PHASE2","title":"ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2021-10-01","conditions":["Diffuse Large B Cell Lymphoma"],"enrollment":31,"completionDate":"2025-12-01"},{"nctId":"NCT05933967","phase":"PHASE2","title":"A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2023-06-01","conditions":["The First Affiliated Hospital of Nanchang University"],"enrollment":31,"completionDate":"2026-12-30"},{"nctId":"NCT05900765","phase":"PHASE2","title":"A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-06-14","conditions":["Classical Hodgkin Lymphoma"],"enrollment":54,"completionDate":"2026-06-30"},{"nctId":"NCT05896813","phase":"NA","title":"CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-03-01","conditions":["Newly Diagnosed Peripheral T-cell Lymphoma"],"enrollment":30,"completionDate":"2025-01-01"},{"nctId":"NCT05809180","phase":"NA","title":"Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-01-04","conditions":["Diffuse Large B Cell Lymphoma"],"enrollment":35,"completionDate":"2026-07-03"},{"nctId":"NCT05777369","phase":"NA","title":"R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-03","conditions":["Diffuse Large B-cell Lymphoma"],"enrollment":30,"completionDate":"2024-08"},{"nctId":"NCT00199056","phase":"PHASE4","title":"German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)","status":"COMPLETED","sponsor":"Goethe University","startDate":"1999-10","conditions":["Adult Acute Lymphocytic Leukemia"],"enrollment":225,"completionDate":"2005-12"},{"nctId":"NCT05498259","phase":"PHASE2","title":"Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-07-27","conditions":["Diffuse Large B-Cell Lymphoma"],"enrollment":46,"completionDate":"2025-01-01"},{"nctId":"NCT00199082","phase":"PHASE4","title":"Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults","status":"COMPLETED","sponsor":"Nicola Goekbuget","startDate":"2002-07","conditions":["Burkitt's Lymphoma","Burkitt's Leukemia","Mediastinal Neoplasms","Lymphoblastic Lymphoma","Large Cell Anaplastic Lymphoma"],"enrollment":650,"completionDate":"2010-06"},{"nctId":"NCT00198991","phase":"PHASE4","title":"German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)","status":"COMPLETED","sponsor":"Goethe University","startDate":"2003-04","conditions":["Adult Acute Lymphocytic Leukemia"],"enrollment":1883,"completionDate":"2013-06-30"},{"nctId":"NCT01458730","phase":"PHASE2","title":"Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2007-05","conditions":["Central Nervous System Lymphoma"],"enrollment":66,"completionDate":"2022-08"},{"nctId":"NCT05428670","phase":"PHASE2","title":"The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2022-06-15","conditions":["Diffuse Large B Cell Lymphoma"],"enrollment":150,"completionDate":"2025-06-30"},{"nctId":"NCT01117441","phase":"PHASE3","title":"International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"University Hospital Schleswig-Holstein","startDate":"2010-06","conditions":["Leukemia"],"enrollment":6136,"completionDate":"2021-12-31"},{"nctId":"NCT01724879","phase":"PHASE2","title":"Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)","status":"COMPLETED","sponsor":"Goethe University","startDate":"2011-11","conditions":["Philadelphia Positive Acute Lymphoblastic Leukemia"],"enrollment":19,"completionDate":"2015-09"},{"nctId":"NCT05164770","phase":"PHASE3","title":"Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Shandong Provincial Hospital","startDate":"2021-03-01","conditions":["High Grade B-Cell Lymphoma, Not Otherwise Specified","High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements","Diffuse Large B Cell Lymphoma","B-cell Non Hodgkin Lymphoma","Mantle Cell Lymphoma"],"enrollment":160,"completionDate":"2024-12-31"},{"nctId":"NCT05097443","phase":"PHASE3","title":"Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Shandong Provincial Hospital","startDate":"2021-04-15","conditions":["High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements","High Grade B-Cell Lymphoma, Not Otherwise Specified","Diffuse Large B-cell Lymphoma","Mantle Cell Lymphoma","B-cell NonHodgkin Lymphoma"],"enrollment":130,"completionDate":"2024-12-31"},{"nctId":"NCT05049473","phase":"PHASE2","title":"Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.","status":"UNKNOWN","sponsor":"PETHEMA Foundation","startDate":"2014-01","conditions":["Mature B-Cell Leukemia Burkitt Type","Burkitt Lymphoma (BL)","Unclassifiable Lymphoma Between DCBL and BL"],"enrollment":100,"completionDate":"2024-01"},{"nctId":"NCT05040555","phase":"NA","title":"R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden","status":"RECRUITING","sponsor":"oubai, MD/PhD","startDate":"2021-08-30","conditions":["Diffuse Large B Cell Lymphoma","Follicular Lymphoma Grade 3B"],"enrollment":64,"completionDate":"2028-09-01"},{"nctId":"NCT01156883","phase":"NA","title":"Combination Chemotherapy in Treating Young Adult Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2010-04","conditions":["Leukemia"],"enrollment":76,"completionDate":"2017-10-31"},{"nctId":"NCT04899570","phase":"PHASE2","title":"Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-04-01","conditions":["Intravascular Large B-Cell Lymphoma"],"enrollment":20,"completionDate":"2025-04-01"},{"nctId":"NCT04843267","phase":"PHASE2","title":"A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CT","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2021-05-01","conditions":["Hodgkin Lymphoma","Chemotherapy Effect"],"enrollment":30,"completionDate":"2025-05-01"},{"nctId":"NCT02867566","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2016-08-22","conditions":["Diffuse, Large B-Cell, Lymphoma"],"enrollment":420,"completionDate":"2019-12-26"},{"nctId":"NCT01528085","phase":"PHASE2","title":"Evaluation of Efficacy and Safety of Nilotinib in Combination With Chemotherapy in Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Goethe University","startDate":"2012-01","conditions":["Philadelphia Chromsome Positive Acute Lymphoblastic Leukemia"],"enrollment":79,"completionDate":"2020-03-10"},{"nctId":"NCT04152577","phase":"PHASE4","title":"R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL","status":"UNKNOWN","sponsor":"Shandong Provincial Hospital","startDate":"2019-06-05","conditions":["Lymphoma, B-Cell"],"enrollment":200,"completionDate":"2022-01-01"},{"nctId":"NCT04026269","phase":"PHASE1,PHASE2","title":"Clinical Efficacy of MOAP Regimen for Relapsed/Refractory cHL as a Rescue Therapy After DP Regimen","status":"UNKNOWN","sponsor":"Han weidong","startDate":"2019-07-30","conditions":["Hodgkin Lymphoma"],"enrollment":30,"completionDate":"2020-12-31"},{"nctId":"NCT02042690","phase":"PHASE3","title":"Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients","status":"COMPLETED","sponsor":"Peking University","startDate":"2014-07","conditions":["Acute Lymphoblastic Leukemia"],"enrollment":131,"completionDate":"2019-04"},{"nctId":"NCT02767674","phase":"PHASE3","title":"Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2016-05","conditions":["Diffuse Large B Cell Lymphoma"],"enrollment":258,"completionDate":"2020-12"},{"nctId":"NCT00136565","phase":"PHASE2","title":"Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma","status":"COMPLETED","sponsor":"Lymphoma Study Association","startDate":"2006-01-08","conditions":["Peripheral T-cell Lymphoma"],"enrollment":60,"completionDate":"2011-04-18"},{"nctId":"NCT00135499","phase":"PHASE3","title":"R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma","status":"TERMINATED","sponsor":"Lymphoma Study Association","startDate":"2001-10-16","conditions":["Lymphoma, Large-Cell, Diffuse"],"enrollment":138,"completionDate":"2010-04-27"},{"nctId":"NCT03631862","phase":"PHASE4","title":"Treatment of Newly Diagnosed Peripheral T-cell Lymphoma","status":"UNKNOWN","sponsor":"Zhengzhou University","startDate":"2018-09-01","conditions":["Newly Diagnosed Peripheral T-cell Lymphoma"],"enrollment":100,"completionDate":"2019-12-31"},{"nctId":"NCT01659099","phase":"PHASE3","title":"GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma","status":"TERMINATED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2012-09","conditions":["Diffuse Large B Cell Lymphoma CD20 Positive"],"enrollment":671,"completionDate":"2017-12-31"},{"nctId":"NCT03018626","phase":"PHASE3","title":"R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2017-07-27","conditions":["Lymphoma, Large B-Cell, Diffuse"],"enrollment":402,"completionDate":"2021-01"},{"nctId":"NCT02871869","phase":"PHASE2,PHASE3","title":"Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma","status":"UNKNOWN","sponsor":"Xinjiang Medical University","startDate":"2016-09","conditions":["Diffuse, Large B-Cell, Lymphoma"],"enrollment":316,"completionDate":"2021-12"},{"nctId":"NCT00554164","phase":"PHASE3","title":"Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas","status":"COMPLETED","sponsor":"University Hospital, Essen","startDate":"2007-11","conditions":["Lymphoma, High-grade"],"enrollment":1073,"completionDate":"2017-03"},{"nctId":"NCT01173887","phase":"PHASE2","title":"Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2010-07","conditions":["Adult T-cell Leukemia-Lymphoma"],"enrollment":44,"completionDate":"2012-04"},{"nctId":"NCT03042429","phase":"PHASE3","title":"Combination Chemotherapy Followed by Stem Cell Transplant in High-risk Neuroblastoma Patients","status":"COMPLETED","sponsor":"University of Cologne","startDate":"2007-01-01","conditions":["Neuroblastoma"],"enrollment":360,"completionDate":"2016-12-31"},{"nctId":"NCT02987244","phase":"PHASE1,PHASE2","title":"Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2016-03","conditions":["T Cell Non-Hodgkin's Lymphoma"],"enrollment":100,"completionDate":"2023-03"},{"nctId":"NCT00128037","phase":"PHASE2","title":"Trial of Pre-operative Chemoradiotherapy Followed by Surgical Resection in Pancoast Tumors (JCOG 9806)","status":"COMPLETED","sponsor":"Japan Clinical Oncology Group","startDate":"1999-05","conditions":["Pulmonary Neoplasm"],"enrollment":75,"completionDate":"2006-02"},{"nctId":"NCT00920153","phase":"PHASE3","title":"Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma","status":"TERMINATED","sponsor":"French Innovative Leukemia Organisation","startDate":"2008-05","conditions":["Lymphoma"],"enrollment":442,"completionDate":"2016-03"},{"nctId":"NCT00317408","phase":"NA","title":"Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma","status":"UNKNOWN","sponsor":"European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma","startDate":"2004-04","conditions":["Lymphoma"],"enrollment":96,"completionDate":""},{"nctId":"NCT00526318","phase":"NA","title":"Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma","status":"UNKNOWN","sponsor":"German Society for Pediatric Oncology and Hematology GPOH gGmbH","startDate":"2007-01","conditions":["Neuroblastoma"],"enrollment":360,"completionDate":""},{"nctId":"NCT00759824","phase":"PHASE2","title":"A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide","status":"COMPLETED","sponsor":"European Lung Cancer Working Party","startDate":"2008-09","conditions":["Small Cell Lung Carcinoma"],"enrollment":64,"completionDate":"2014-06"},{"nctId":"NCT00613457","phase":"PHASE3","title":"Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Associazione Italiana Ematologia Oncologia Pediatrica","startDate":"2000-09","conditions":["Leukemia"],"enrollment":2039,"completionDate":"2006-07"},{"nctId":"NCT01290120","phase":"PHASE2","title":"Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Northern Italy Leukemia Group","startDate":"2002-11","conditions":["Burkitt Lymphoma","B-ALL"],"enrollment":182,"completionDate":"2014-06"},{"nctId":"NCT00002802","phase":"PHASE3","title":"Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"1990-07","conditions":["Neuroblastoma"],"enrollment":500,"completionDate":"2003-09"},{"nctId":"NCT00003240","phase":"PHASE3","title":"Standard Therapy Given With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"National Cancer Institute (NCI)","startDate":"1995-10","conditions":["Lung Cancer"],"enrollment":1800,"completionDate":""},{"nctId":"NCT00002531","phase":"PHASE2","title":"Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia","status":"UNKNOWN","sponsor":"Johann Wolfgang Goethe University Hospital","startDate":"1993-01","conditions":["Leukemia"],"enrollment":0,"completionDate":""},{"nctId":"NCT00002887","phase":"PHASE1","title":"Hydroxyurea Plus Combination Chemotherapy in Patients With Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Ottawa Regional Cancer Centre","startDate":"1995-07","conditions":["Lung Cancer"],"enrollment":30,"completionDate":""},{"nctId":"NCT00410631","phase":"PHASE3","title":"Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma","status":"UNKNOWN","sponsor":"German Society for Pediatric Oncology and Hematology GPOH gGmbH","startDate":"2004-10","conditions":["Neuroblastoma"],"enrollment":642,"completionDate":""},{"nctId":"NCT00002532","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia","status":"UNKNOWN","sponsor":"Hannover Medical School","startDate":"1993-01","conditions":["Leukemia"],"enrollment":0,"completionDate":""},{"nctId":"NCT00017225","phase":"PHASE2","title":"Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma","status":"COMPLETED","sponsor":"German Society for Pediatric Oncology and Hematology GPOH gGmbH","startDate":"1997-05","conditions":["Neuroblastoma"],"enrollment":0,"completionDate":"2002-02"},{"nctId":"NCT00430118","phase":"PHASE3","title":"Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"University Hospital Schleswig-Holstein","startDate":"2000-07","conditions":["Leukemia"],"enrollment":4559,"completionDate":"2012-01"},{"nctId":"NCT00002823","phase":"PHASE3","title":"Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"1995-02","conditions":["Lung Cancer"],"enrollment":3300,"completionDate":""},{"nctId":"NCT00003209","phase":"PHASE3","title":"Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1997-12","conditions":["Cervical Cancer"],"enrollment":700,"completionDate":""},{"nctId":"NCT00003728","phase":"PHASE3","title":"Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1998-12","conditions":["Leukemia","Lymphoma"],"enrollment":1500,"completionDate":""},{"nctId":"NCT00199017","phase":"PHASE4","title":"German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults","status":"COMPLETED","sponsor":"Johann Wolfgang Goethe University Hospital","startDate":"2004-04","conditions":["Lymphoma, Lymphoblastic"],"enrollment":75,"completionDate":""},{"nctId":"NCT00199004","phase":"PHASE4","title":"Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab","status":"COMPLETED","sponsor":"Johann Wolfgang Goethe University Hospital","startDate":"2004-04","conditions":["Adult Acute Lymphocytic Leukemia"],"enrollment":60,"completionDate":"2009-03"},{"nctId":"NCT00764907","phase":"PHASE3","title":"Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia","status":"UNKNOWN","sponsor":"University Hospital, Motol","startDate":"2002-11","conditions":["Leukemia"],"enrollment":4000,"completionDate":""},{"nctId":"NCT00689845","phase":"NA","title":"Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma","status":"UNKNOWN","sponsor":"University Hospital Southampton NHS Foundation Trust","startDate":"2007-06","conditions":["Lymphoma"],"enrollment":120,"completionDate":""},{"nctId":"NCT00869284","phase":"PHASE2","title":"Long-Term Follow-up of Tandem High-Dose Therapy With Peripheral Blood Stem Cell for Adults With High-Risk Age-Adjusted IPI Aggressive Non-Hodgkin's Lymphomas","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"1994-10","conditions":["Lymphoma"],"enrollment":45,"completionDate":"2009-02"},{"nctId":"NCT00696735","phase":"PHASE3","title":"High-Dose Therapy Treatment in Patients With Follicular Lymphoma","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"1994-06","conditions":["Follicular Lymphoma"],"enrollment":172,"completionDate":"2006-05"},{"nctId":"NCT00226473","phase":"PHASE4","title":"Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma","status":"UNKNOWN","sponsor":"Dermatologic Cooperative Oncology Group","startDate":"2001-09","conditions":["Metastatic Melanoma"],"enrollment":200,"completionDate":"2005-09"},{"nctId":"NCT00144053","phase":"PHASE3","title":"A Phase Ⅲ Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"West Japan Thoracic Oncology Group","startDate":"2001-04","conditions":["Lung Cancer"],"enrollment":450,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000171809","NDDF":"003505","UNII":"RSA8KO39WH","VUID":"4025282","CHEBI":"CHEBI:32295","VANDF":"4025282","INN_ID":"3927","RXNORM":"11204","UMLSCUI":"C0042682","chemblId":"CHEMBL3989543","ChEMBL_ID":"CHEMBL238071","KEGG_DRUG":"D01769","DRUGBANK_ID":"DB00309","PUBCHEM_CID":"40839","SNOMEDCT_US":"349851002","SECONDARY_CAS_RN":"59917-39-4","MESH_DESCRIPTOR_UI":"D014751"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"35.0 hours","clearance":"2.2 mL/min/kg","volumeOfDistribution":"5.0 L/kg"},"publicationCount":1512,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01CA03","allCodes":["L01CA03"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"OTHER","regulator":"YEAR INTRODUCED","status":"approved","approval_date":"1979-01-01T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:59:05.583642+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}